


CLAIMS

1. A compound of Formula (I-b):



hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R^1 ;

L is absent, C_1 - C_6 -alkylene, C_1 - C_6 -heteroalkylene, -O-, -C(O)-, -N(R^3)-, -N(R^3)C(O)-, or -C(O)N(R^3)-, wherein each alkylene and heteroalkylene is optionally substituted with one or more R^4 ;

M and P are each independently C(R^2) or N;

X and Y are each independently C(R^{5a}), C(R^{5a})(R^{5b}), N, or N(R^{5c}), wherein the bond between X and Y may be a single or double bond as valency permits, and wherein X and Y may not both be C(R^{5a})(R^{5b}) or C(R^{5a});

each R^1 is independently hydrogen, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -heteroalkyl, C_1 - C_6 -haloalkyl, cycloalkyl, heterocyclyl, aryl, C_1 - C_6 alkylene-aryl, C_1 - C_6 alkenylene-aryl, C_1 - C_6 alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, -OR^A, -NR^BR^C, -NR^BC(O)R^D, -NO₂, -C(O)NR^BR^C, -C(O)R^D, -C(O)OR^D, -SR^E, or -S(O)_xR^D, wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8 ; or

two R^1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R^8 ;

each R^2 is independently hydrogen, halo, cyano, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, or -OR^A;

each R^3 is independently hydrogen, C_1 - C_6 -alkyl, or C_1 - C_6 -haloalkyl;

each R^4 is C_1 - C_6 -alkyl, C_1 - C_6 -heteroalkyl, C_1 - C_6 -haloalkyl, cycloalkyl, halo, cyano, oxo, -OR^A, -NR^BR^C, -C(O)R^D, or -C(O)OR^D;

each of R^{5a} and R^{5b} is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-heteroalkyl, C₁-C₆-haloalkyl, cycloalkyl, halo, cyano, oxo, -OR^A, -NR^BR^C, -C(O)R^D, or -C(O)OR^D;

R^{5a} and R^{5b}, together with the carbon atom to which they are attached, form an oxo group;

each R^{5c} is hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C(O)R^D;

each R⁷ is independently C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-heteroalkyl, C₁-C₆-haloalkyl, halo, oxo, cyano, NR^BC(O)R^D, -C(O)NR^BR^C, -C(O)R^D, or -SR^E, wherein alkyl, alkenyl, alkynyl, heteroalkyl, and haloalkyl are optionally substituted with one or more R⁹;

R⁸ and R⁹ are each independently C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-heteroalkyl, C₁-C₆-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, -OR^A, -NR^BR^C, -NR^BC(O)R^D, -NO₂, -C(O)NR^BR^C, -C(O)R^D, -C(O)OR^D, -SR^E, or -S(O)_xR^D, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R¹¹;

each R^A is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₆ alkylene-aryl, C₁-C₆ alkylene-heteroaryl, -C(O)R^D, or -S(O)_xR^D;

each of R^B and R^C is independently hydrogen, C₁-C₆ alkyl, C₁-C₆-heteroalkyl, cycloalkyl, heterocyclyl, -OR^A; or

R^B and R^C together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R¹⁰;

each R^D and R^E is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, C₁-C₆ haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₆ alkylene-aryl, or C₁-C₆ alkylene-heteroaryl;

R¹⁰ is C₁-C₆-alkyl or halo;


each R¹¹ is independently C₁-C₆-alkyl, C₁-C₆-heteroalkyl, C₁-C₆-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or -OR^A;

n is 0, 1, 2, 3, or 4; and


x is 0, 1, or 2.


2. The compound of claim 1, wherein A is a monocyclic or bicyclic heterocyclyl.

3. The compound of any one of the preceding claims, wherein A is monocyclic heterocyclyl.
4. The compound of any one of the preceding claims, wherein A is a nitrogen-containing heterocyclyl.
5. The compound of any one of the preceding claims, wherein A is selected from




6. The compound of any one of the preceding claims, wherein A is selected from






7. The compound of any one of the preceding claims, wherein A is selected from



8. The compound of any one of the preceding claims, wherein B is selected from







9. The compound of any one of the preceding claims, wherein B is selected from , , , , , , , , , and .

10. The compound of any one of the preceding claims, wherein B is selected from , , , and .

11. The compound of any one of the preceding claims, wherein L is absent, -O- or -N(R³)- (e.g., -N(CH₃)- or -NH-).

12. The compound of any one of the preceding claims, wherein L is -N(R³)- (e.g., -N(CH₃)- or -NH-).

13. The compound of any one of the preceding claims, wherein  is selected from , , and .

14. The compound of any one of the preceding claims, wherein each of M and P is independently C(R²) (e.g., CH).




15. The compound of any one of the preceding claims, wherein one of X and Y is C(R^{5a})(R^{5b}) and the other of X and Y is N(R^{5c}).

16. The compound of claim 15, wherein R^{5a} and R^{5b}, together with the carbon atom to which they are attached, form an oxo group.


17. The compound of any one of the preceding claims, wherein X is N(R^{5c}) (e.g., NH) and Y is C(R^{5a})(R^{5b}) (e.g., C(O)).

18. The compound of any one of the preceding claims, wherein X is N and Y is C(R^{5a}) (e.g., C(OCH₃)).

19. The compound of any one of the preceding claims, wherein one of X and Y is C(O) and the other of X and Y is NH.


20. The compound of any one of the preceding claims, wherein  is selected from  and .

21. The compound of any one of claims 1-19, wherein the compound is a compound of Formula (I-c):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R², R^{5c}, R⁷, m, n, and subvariables thereof are as described in claim 1.

22. The compound of any one of claims 1-19, wherein the compound is a compound of Formula (I-d):




or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A¹ is 6-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R¹;

B¹ is 5-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R¹; and


L, R¹, R², R^{5c}, R⁷, m, n, and subvariables thereof are as described in claim 1.

23. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-e):




or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R², R^{5a}, R⁷, m, n, and subvariables thereof are as described in claim 1.

24. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-f):




or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, X, Y, R³, R⁷, n, and subvariables thereof are as described in claim 1.

25. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-g):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, L, R', R², R⁷, m, n, and subvariables thereof are as described in claim 1, R' is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-heteroalkyl, C₁-C₆-haloalkyl, cycloalkyl, -C(O)R^D, or -C(O)OR^D.

26. The compound of any one of claims 1-20, wherein the compound is a compound of Formula (I-h):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A¹ is 6-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R¹;

B¹ is 5-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R¹; and

L, R^{5a}, R², R⁷, m, n, and subvariables thereof are as described in claim 1.

27. The compound of any one of the preceding claims, wherein the compound is selected from any one of the compounds shown in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

28. A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient.

29. The compound of any one of claims 1-27, or the pharmaceutical composition of claim 28, wherein the compound alters a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

30. The compound of any one of claims 1-27, or the pharmaceutical composition of claim 28, wherein the compound binds to a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

31. The compound of any one of claims 1-27, or the pharmaceutical composition of claim 28, wherein the compound stabilizes a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).
32. The compound of any one of claims 1-27, or the pharmaceutical composition of claim 28, wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.
33. The compound of any one of claims 1-27, or the pharmaceutical composition of claim 28, wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.
34. A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA), and a compound of Formula (I) according to any one of claims 1-27, comprising contacting the nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) with a compound of Formula (I).
35. The method of claim 34, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I).
36. A method of altering the conformation of a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) according to any one of claims 1-27 or the pharmaceutical composition of claim 28.
37. The method of claim 36, wherein the altering comprises forming a bulge in the nucleic acid.

38. The method of claim 36, wherein the altering comprises stabilizing a bulge in the nucleic acid.
39. The method of claim 36, wherein the altering comprises reducing a bulge in the nucleic acid.
40. The method of any one of any one of claims 36-39, wherein the nucleic acid comprises a splice site.
41. A composition for use in treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) according to any one of claims 1-27 or the pharmaceutical composition of claim 28.
42. The composition for use of claim 41, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).
43. The composition for use of claim 41, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.
44. The composition for use of claim 41, wherein the disease or disorder comprises neurological disease or disorder.
45. The composition for use of claim 41, wherein the disease or disorder comprises Huntington's disease.